1.36
-0.02(-1.45%)
Currency In USD
| Previous Close | 1.38 |
| Open | 1.37 |
| Day High | 1.45 |
| Day Low | 1.36 |
| 52-Week High | 7.8 |
| 52-Week Low | 1.24 |
| Volume | 371,308 |
| Average Volume | 786,003 |
| Market Cap | 87.37M |
| PE | -0.88 |
| EPS | -1.55 |
| Moving Average 50 Days | 2.39 |
| Moving Average 200 Days | 4.24 |
| Change | -0.02 |
If you invested $1000 in Inozyme Pharma, Inc. (INZY) since IPO date, it would be worth $77.54 as of February 05, 2025 at a share price of $1.36. Whereas If you bought $1000 worth of Inozyme Pharma, Inc. (INZY) shares 3 years ago, it would be worth $198.54 as of February 05, 2025 at a share price of $1.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
GlobeNewswire Inc.
Jan 10, 2025 1:00 PM GMT
- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and stabilization or reduction in ectopic calcification and hypophos
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 27, 2024 1:30 PM GMT
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel fun
Inozyme Pharma to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 11, 2024 1:30 PM GMT
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel fun